CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

CB307: A novel T-cell costimulatory Humabody® VH therapeutic for PSMA-positive tumors (PEGS 2019 poster)

View Poster

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019

View PDF

Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®

Crescendo Biologics announces early licensing by Takeda
of first oncology-targeted Humabody®

View PDF

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018

View PDF

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic

Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO
partner, as it advances towards the clinic

View PDF